Top Quality Loss Weight Semaglutide 2mg/5mg Price for Bulk CAS 910463-68-2

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: White Freeze-Dried Powder
• Purity: >99%
• Model NO.: Frazer-Semaglutide
• Appearance: White Freeze-Dried Powder
• CAS No: 910463-68-2
• Shelf Life: 2 Years
• Test Method: HPLC
• MOQ: 1box
• Storage: Store Cool Dry Place
• Resource: Natural
• Quality Requirement: Strictly Quality Control
• Market: Worldwide
• Service: Welcome to Visit Us
• Delivery Time: 7-10days
• Transport Package: Foil Bag
• Specification: 99%
• Trademark: Xi′an Frazer Biotech Co., Ltd.
• Origin: China
• Production Capacity: 200box/Month

Product Description

Top Quality loss weight Semaglutide 2mg/5mg Price for Bulk CAS 910463-68-2

 

Description:

Ry-belsus (semaglutide) is used together with diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus.
Ry-belsus is usually given after other diabetes medicines have been tried without success.

The FDA approved once-weekly semaglutide injection for chronic weight management in adults with obesity or with overweight and at least one weight-related condition, according to an agency press release.

Weekly semaglutide 2.4 mg (W-egovy, Novo Nordisk), a GLP-1 receptor agonist, is the first-approved drug for chronic weight management in adults with general obesity or overweight since 2014. Semaglutide is indicated for chronic weight management in adults with a BMI of 27 kg/m² or greater who have at least one weight-related comorbidity, such as type 2 diabetes or hypertension, or in adults with a BMI of at least 30 kg/m²

Semaglutide 1 mg injection (O-zempic) was first approved as a treatment for type 2 diabetes in 2017.

Safety and efficacy of semaglutide 2.4 mg was assessed in four 68-week trials. Three were randomized, double-blind, placebo-controlled trials, including 16 weeks of dose increases, and one was a double-blind, placebo-controlled, randomized withdrawal trial in which patients assigned semaglutide either continued treatment or switched to a placebo

Semaglutide 2.4 mg should not be used in combination with other semaglutide-containing products, other GLP-1 receptor agonists or other products intended for weight loss, including prescription drugs, over-the-counter drugs and herbal products, according to the release. Semaglutide 2.4 mg has not been studied in patients with a history of pancreatitis.

This is a once-weekly injectable, which is more tolerable way of managing obesity vs. other treatments. The STEP study data showed semaglutide 2.4 mg crosses the magic threshold of 10% weight loss for many people who received it. This is another tool that will allow clinicians to better manage obesity.

Function

• Diabetes Type 2 Medicine
• Oral GLP-1RA Medication
• Weight Loss
• Diabetes Mellitus
• Obesity
• Diabetic Coma (in DM Type II)
• Diabetic Ketoacidosis (in DM Type II)
• Cardiovascular Risk Reduction